%0 Journal Article
%T Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension
%A Abolghasmi Rozita
%A Taziki Omolbanin
%J Saudi Journal of Kidney Diseases and Transplantation
%D 2011
%I Medknow Publications
%X To determine the antihypertensive benefit of adding low dose sprinolactone to multi-drug regimens that included a diuretic, a calcium channel blocker and angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with moderately severe chronic kidney disease (CKD) [glomerular filtration rate (GFR) 25-50 mL/min] and resistant hyper-tension, we studied 41 patients randomly divided into two groups: group 1: patients who received placebo as spironolactone and group 2: patients who received spironolactone 25-50 mg/day. The patients were evaluated during follow-up at the 6th and 12th weeks. The mean decrease in systolic and diastolic blood pressure after 6 weeks of spironolactone was 33 ¡À 8 and 13 ¡À 2 mmHg, respectively, and it was maintained after 12 weeks of spironolactone wherein the values were 36 ¡À 10 and 12 ¡À 2 mmHg, respectively, while there was no change in the blood pressure in the control group. Hyperkalemia (serum potassium >5.5 meq/L) occurred in one subject in the spironolactone group. We conclude that low-dose spironolactone may provide a significant additive blood pressure reduction in CKD patients (stage 2 and 3) with resistant hypertension.
%U http://www.sjkdt.org/article.asp?issn=1319-2442;year=2011;volume=22;issue=1;spage=75;epage=78;aulast=Abolghasmi